Salih H R, Schmetzer H M, Burke C, Starling G C, Dunn R, Pelka-Fleischer R, Nuessler V, Kiener P A
Department of Immunology, Inflammation, and Pulmonary Diseases, Pharmaceutical Research Institute, Bristol-Myers Squibb, Princeton, NJ 08540, USA.
J Immunol. 2001 Oct 1;167(7):4059-66. doi: 10.4049/jimmunol.167.7.4059.
Expression of CD137 ligand (4-1BBL), a member of the TNF family of proteins, has been reported on several types of APCs, various carcinoma cells, and can be induced on activated T cells. In this study, we report that the soluble ligand was released constitutively at low levels from leukocytes and at higher levels following cellular activation. Release from cells was blocked by addition of a metalloproteinase inhibitor which concomitantly caused the accumulation of 4-1BBL on the cell surface. In addition, we show that a soluble form of 4-1BBL was present at high levels in the sera of some patients with various hematological diseases, but only at low levels in healthy donors. Soluble 4-1BBL was active in that it competed with recombinant 4-1BBL for binding to the 4-1BB receptor and was able to costimulate IL-2 and IFN-gamma release from peripheral T cells. These results indicate that the release of soluble 4-1BBL from the cell surface is mediated by one or more sheddases and likely regulates 4-1BB-4-1BBL interactions between cells in vivo. Cleavage of 4-1BBL to an active soluble form would alter both proximal and distal cellular responses, including cell survival and costimulatory or inflammatory responses, that are mediated through the 4-1BB pathway. This, in turn, would likely alter disease progression or outcome.
肿瘤坏死因子(TNF)家族蛋白成员之一的CD137配体(4-1BBL),已被报道在多种类型的抗原呈递细胞(APC)、各种癌细胞上表达,并且在活化的T细胞上也可被诱导表达。在本研究中,我们报道可溶性配体在白细胞中以低水平持续释放,而在细胞活化后释放水平更高。细胞释放被金属蛋白酶抑制剂的添加所阻断,这同时导致4-1BBL在细胞表面的积累。此外,我们表明,可溶性4-1BBL在一些患有各种血液系统疾病的患者血清中高水平存在,但在健康供体中仅低水平存在。可溶性4-1BBL具有活性,因为它与重组4-1BBL竞争结合4-1BB受体,并且能够共刺激外周T细胞释放白细胞介素-2(IL-2)和γ干扰素(IFN-γ)。这些结果表明,可溶性4-1BBL从细胞表面的释放是由一种或多种蛋白酶介导的,并且可能在体内调节细胞间的4-1BB-4-1BBL相互作用。4-1BBL切割成活性可溶性形式会改变近端和远端细胞反应,包括通过4-1BB途径介导的细胞存活以及共刺激或炎症反应。反过来,这可能会改变疾病的进展或结果。